Novavax Delays Seeking U.S. Regulatory Approval for Covid-19 Vaccine

Novavax Inc.said it would delay seeking U.S. emergency authorization for its Covid-19 vaccine until the fourth quarter as it works to complete the manufacturing portion of its application. “The manufacturing part has been the most work that we have to do,” Stanley Erck, Novavax chief executive, said in an interview Thursday. “Hopefully October for the FDA, but we don’t have a date picked.” He said Novavax plans to apply for approval with U.K. regulators in September and would follow shortly after in Canada and Australia.